Group items tagged

The launch of Protease Inhibitors (PIs) accelerated the pace of innovation and impressive Sustained Virologic Response (SVR) rates by oral IFN free drug combinations. Freedom from IFN, treating all genotypes and vaccines could bring a sea of change in the HCV therapy class area in the future. Roche set the trend with the acquisition of Anadys for total of USD 230 mn followed by GILD buying VRUS for USD 11 bn, Bristol-Myers Squibb (BMY) acquiring Inhibitex for USD 2.5 bn, VRTX acquiring Virochem in 2009 for USD 375 mn, In-licensed Alios VX-135 in 2012 for total of USD 775 mn and Abbott in-licensed Enantas ABT-450 for total of USD 310 mn.

Rising competition, retention or recruitment of skilled staff, market uncertainty, and responding to pricing pressure were the leading business concerns for the global oil and gas industry in 2013. Middle East, Brazil, India, China and Indonesia were forecasted to be the important emerging markets to offer growth in 2013. Capital expenditure towards facility expansion, machinery and equipment purchase and new product development was estimated to increase in 2013. The top three priorities for global oil and gas industry upstream oil and gas companies in 2013 were to expand in current market, improve operational efficiency and focus on sustainability.